Kailera Therapeutics · 4 days ago
Senior Director, Toxicology
Kailera is committed to developing therapies that transform lives and improve health. The Senior Director of Toxicology will lead the non-clinical safety strategy across multiple development programs, combining scientific expertise with cross-functional leadership to ensure alignment with clinical development and regulatory compliance.
BiotechnologyPharmaceuticalTherapeutics
Responsibilities
Develop and lead non-clinical strategies across development programs, serving as the functional lead for non-clinical on cross-functional Program Teams
Execute functional business plans and contribute to the development of broader functional strategy to achieve key business objectives
Make program decisions guided by functional priorities and company strategy that impact the results of core business functions and facilitate cross-functional collaboration
Provide technical leadership on strategically critical initiatives, including study design, data interpretation, and risk assessment, maintaining external recognition as an expert in the field
Oversee CROs conducting non-clinical development studies (e.g. chronic tox, carcinogenicity, DART, mechanistic studies), ensuring scientific rigor and regulatory compliance
Author, review, and approve regulatory submissions (e.g., INDs, NDAs, Investigator’s Brochures, PIPs, briefing books, white papers) and represent Kailera and non-clinical development in meetings with regulatory agencies
Apply in-depth knowledge of own function and broad industry awareness to differentiate Kailera from the competition
Solve highly complex problems and lead others in addressing issues of diverse scope, applying ingenuity, sophisticated analytical thought and creative solutions
Apply broad industry and commercial awareness to drive financial and operational performance ensuring accurate budgeting and resource allocation
Review information and data in the context of mid- and long-term project goals, directing the course of research and influencing organizational vision
Use independent judgement to determine methods, techniques, and criteria for obtaining broad results
Present non-clinical findings and strategic recommendations to senior leadership and external stakeholders
Influence decision-making across functions by translating complex data into actionable insights
Take the perspective of others into account when making final decisions related to operational and administrative matters
Lead and mentor a high-performing non-clinical development team, fostering a culture of scientific excellence, collaboration, and continuous feedback and development
Lead with trust, understanding, and adaptability to drive followership across the organization
Direct the activities of cross-functional, complex, multi-disciplinary projects or teams, including prioritization and resource planning
Mentor team members to achieve project goals and support career development
Qualification
Required
Proven track record of leading non-clinical contributions to complex, multi-disciplinary projects and teams
Proven track record of successful preparation, submission, and acceptance of non-clinical component of regulatory filings such as INDs, PSPs, NDAs, BLAs
Deep understanding of GLP, regulatory requirements, and non-clinical development strategies
Strong communication, leadership, execution and strategic thinking skills
Bachelor's degree with 12+ years of relevant experience, or an advanced degree (PhD, PharmD, DVM) with 10+ years of experience in toxicology or related field
Preferred
DABT or equivalent strongly preferred
Benefits
Comprehensive health coverage
Flexible time off
Paid holidays
Year-end shutdown
Monthly wellness stipend
Generous 401(k) match
Tuition reimbursement
Commuter benefits
Disability and life insurance
Annual bonus opportunities
Equity grants
Company
Kailera Therapeutics
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Funding
Current Stage
Growth StageTotal Funding
$1BKey Investors
Bain Capital Private Equity
2025-10-14Series B· $600M
2024-10-01Series A· $400M
Leadership Team
Recent News
2026-01-05
2025-12-24
2025-12-17
Company data provided by crunchbase